Compare · ETNB vs NVO
ETNB vs NVO
Side-by-side comparison of 89bio Inc. (ETNB) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ETNB and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 1550.1x ETNB ($123.3M).
- Over the past year, ETNB is up 48.0% and NVO is down 45.0% - ETNB leads by 93.0 points.
- NVO has hit the wire 8 times in the past 4 weeks while ETNB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 15 for ETNB).
- Company
- 89bio Inc.
- Novo Nordisk A/S
- Price
- $14.85+0.13%
- $43.27+1.11%
- Market cap
- $123.3M
- $191.15B
- 1M return
- +1.09%
- -7.88%
- 1Y return
- +47.98%
- -45.02%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 0
- 8
- Recent ratings
- 15
- 25
89bio Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ETNB
- SEC Form EFFECT filed by 89bio Inc.
- SEC Form SCHEDULE 13G filed by 89bio Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by 89bio Inc.
- SEC Form 15-12G filed by 89bio Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.
- Director Ra Capital Management, L.P. returned 19,889,683 shares to the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by 89bio Inc.
- SEC Form 4 filed by Director Laporte Kathleen
- Director Hayden Michael R closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Martins Ryan was granted 35,000 shares, closing all direct ownership in the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care